statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor...

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lexeo Therapeutics expects cash to fund operations into 2027

Lexeo Therapeutics reports Q4 EPS (86c), consensus (73c)

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo Therapeutics announces $95M private equity placement

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management...

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics GAAP EPS of -$0.86 misses by $0.15...

Lexeo Therapeutics GAAP EPS of -$0.86 misses by $0.15

Lexeo Therapeutics, Inc. (NASDAQ:LXEO  Get Free Report) has been assigned an average recommendation of Buy from the six analysts that are presently covering the company...

Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $20.80

Lexeo Therapeutics, Inc. (LXEO) has released an update to notify the public and investors about a regulation fd disclosure. Lexeo Therapeutics, Inc...

Lexeo Therapeutics Bolsters Leadership with Key Hires

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Volume	209,037.00
52-Wk High	$22.33
52-Wk Low	$9.00

LXEO Lexeo Therapeutics Inc.

About

Feed

News

Fundamentals